Data Presented at 2nd Healthy Lung Summit 2018 to Demonstrate Impact of AstraZeneca#s Healthy Lung Partnership Programme

Food and Healthcare Press Releases Tuesday December 4, 2018 08:00
TAIPEI, Taiwan--4 Dec--PRNewswire/InfoQuest

Deepening commitment to drive improvements for patients with respiratory disease across Asia, AstraZeneca with Business Sweden, The Swedish Trade & Invest Council in Taiwan, hosts the second Healthy Lung Summit, ahead of the 2018 Asia Pacific Society of Respirology Meeting

Building on the continued success of the Healthy Lung Programme, AstraZeneca with Business Sweden, The Swedish Trade & Invest Council in Taiwan, hosted the 2nd Healthy Lung Summit this week, bringing together experts from across nine countries to share progress made by regional taskforces and develop best practice approaches. Data presented from the work of the Healthy Lung Taskforces across the region has:

  • Helped to diagnose the respiratory disease of more than 425,000 new patients
  • Supported the education of more than 22,000 healthcare professionals and more than 24,000 patients
  • Supported the update and/or creation of 10 national guidelines and care pathways
  • Supported the certification of 956 respiratory centres of excellence
For the full multimedia release, click here: MNR landing page link:

The Healthy Lung Programme, is a partnership activity between AstraZeneca, national Governments and professional organisations to raise the profile of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, and build the capability of healthcare systems in these countries to manage these diseases. To date, three bilateral agreements have been secured with Governments across the Asia-Pacific region and 15 formal partnerships secured to improve respiratory care, reaching over close to half a million patients across the region.

As Healthy Lung moves into 2019, activity will focus on expanding its impact to benefit the lives of a far greater number of patients. To do this, National Task Forces are being challenged to:
  • Support additional reforms to help to overcome other established challenges facing care for respiratory disease
  • Improve the measurement of Healthy Lung-related activities, focusing on the development of robust, validated data on impact
  • Share new data with a yet broader audience of policymakers and clinical leaders to demonstrate the value of clinical reform

The second Healthy Lung Summit, organised by AstraZeneca in collaboration with Business Sweden, The Swedish Trade & Invest Council in Taiwan, is part of a continued commitment to help enhance healthcare systems and build sustainable capabilities to improve outcomes for respiratory disease across Asia.

Speaking ahead of the Summit, co-chairs, Professor Meng-Chih Lin, President of Taiwan Society of Pulmonary and Critical Care Medicine and Dr Lee Po-Chang, Director General of the National Health Insurance Administration commented: "This 2nd Healthy Lung Summit offers a chance for countries to learn from each other and share best-practice examples highlighting just what we can achieve by working together nationally and across the region to deliver tangible improvements for patients. We are proud of our achievements to date -- reaching over 130,000 patients and educating over 5,000 doctors -- but there is more to be done and we are committed to accelerating progress to deliver real improvements for future generations."

Asthma affects 315 million adults worldwide[1], and more than 107 million people in Asia Pacific region alone are living alone with asthma[2]. However, less than one third of asthmatics worldwide are treated with preventative therapy[3] and less than ten per cent of COPD patients are seeking treatment[4]. The Healthy Lung Task Force supports collaboration and aims to strengthen relationships between nine countries to improve outcomes for patients with respiratory conditions across the region.

About the Healthy Lung programme

AstraZeneca launched the Healthy Lung Asia programme in nine Asian countries, with the objective of raising among policymakers the profile of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer, and building the capability of healthcare systems in these countries to manage these diseases.

In 2017, Healthy Lung Asia saw the establishment and advancement of Respiratory Task Forces, advancing advocacy and policy initiatives to drive improvement in patient outcomes at a national level.   In 2018, the Healthy Lung Summit brings together those Task Force representatives to discuss progress against their respective objectives, share best practice approaches and design plans for the year ahead.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

For more information, please visit and follow us on Twitter @AstraZeneca.
[1] To T et al. Global asthma prevalence in adults: findings from cross-sectional world health survey. BioMed Central Public Health. 2012: 12(204)
[2] World Health Organization, Global status report on non-communicable diseases 2014.
[3] Bachtlar, D. Prevalence of asthma control test (ACT) in the asthma outpatient Persahabatan Hospital Jakarta in May to July 2009 (thesis). Jakarta: Universitas Indonesia; 2010. Indonesian.
[4] <Reference required -- unreferenced in sustainability report>
Video -
Video -
Video -
Photo -
Photo -
Logo -
Logo -

Latest Press Release

The Menarini Group Announces Meropenem/vaborbactam European Marketing Authorization

- Meropenem/vaborbactam approved on 20th November 2018 by the European Commission for clinical use in adult patients with difficult-to-treat infections - The first combination of a carbapenem and a beta-lactamase inhibitor approved for clinical use in...

Merck Announces FDA Orphan Drug Designation for Bifunctional Immunotherapy M7824 in Biliary Tract Cancer

- FDA grants M7824, an investigational bifunctional immunotherapy, orphan drug designation in biliary tract cancer - First regulatory designation for M7824 following recent presentation of first clinical data in BTC - BTC is a group of rare, aggressive...

Merck in Agreement With Cyclica for AI-augmented Screening Platform to Expand Research Capabilities

- Agreement to screen discovery and early development compounds using artificial intelligence and computational biophysics - Cloud-based in silico platform that screens small molecules to determine polypharmacological profiles - Evaluation to include...

Vitality-linked Insurers to Get 100 million People 20% More Active by 2025

Building on the results of the largest behaviour change study on physical activity, Vitality and its global network of insurers have collectively committed to improving the health of millions over the next seven years. This is in line with the World...

World Congress of Cardiology Cardiovascular Health 2018 Opens in Dubai

- Professor David Wood, President of the World Heart Federation, welcomes more than 5000 cardiologists, doctors, nurses, and health and policy experts from around the world to Dubai for WCC 2018 at a time when the opportunities for a sustainable impact...

Related Topics